Drug class
First-generation phenothiazine antipsychotic; dopamine D2 receptor antagonist
Mechanism of action
Antagonises central dopamine D2 receptors and also interacts with histamine H1, muscarinic and alpha-adrenergic receptors, contributing to antipsychotic, sedative and autonomic effects.
General use cases
- Treatment of psychotic disorders and schizophrenia in countries where promazine remains authorised; other sedative or antiemetic uses are product- and jurisdiction-specific
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
